DLC1 and metastatic malignant neoplasm: It expands the known DLC1 role and opens the prospect that DLC1 introduction, or the inhibition of downstream pathways activated by DLC1 deficiency, could sensitize chemotherapy-resistant metastatic cancer to various pharmacological drugs.